Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

AIDS. 2011 Nov 28;25(18):2301-4. doi: 10.1097/QAD.0b013e32834cdb71.

Abstract

Evidence of the risk of birth defects with efavirenz use is limited. We updated a meta-analysis of birth defects in infants with first trimester efavirenz exposure up to July 2011. In 21 studies, there were 39 defects among live births in 1437 women receiving first trimester efavirenz [2.0%, 95% confidence interval (CI) 0.82-3.18]. The relative risk of defects comparing women on efavirenz-based (1290 live births) and nonefavirenz-based regimens (8122 live births) was 0.85 (95% CI 0.61-1.20). One neural tube defect was observed (myelomeningocele), giving an incidence of 0.07% (95% CI 0.002-0.39).

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Abnormalities, Drug-Induced / epidemiology*
  • Alkynes
  • Anti-HIV Agents / adverse effects*
  • Benzoxazines / adverse effects*
  • Cyclopropanes
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Incidence
  • Neural Tube Defects / chemically induced
  • Neural Tube Defects / epidemiology
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Outcome / epidemiology*
  • Pregnancy Trimester, First
  • Risk Factors
  • Treatment Outcome

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • efavirenz